Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 13Cholangiocarcinoma 2Pancreatic Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Liver Neoplasms 1Hepatocellular Carcinoma with PVTT 1Digestive System Neoplasms 1Differentiated Thyroid Cancer 1Diabetes Mellitus 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma 1Biliary Tract Adenocarcinoma 1Biliary Malignant Tumors 1

Interventions

Paclitaxel 4Oxaliplatin 4Cisplatin 4Radiotherapy 3Ocoxin 3Folfox protocol 3pembrolizumab 2camrelizumab 2apatinib 2anlotinib 2Sunitinib 2Sorafenib 2Imatinib Mesylate 2Gemcitabine 2Fluorouracil 2Drug Therapy 2Capecitabine 2Bevacizumab 2tislelizumab 1sintilimab 1regorafenib 1pyrotinib 1pemigatinib 1genexol-PM 1durvalumab 1donafenib 1copanlisib 1atezolizumab 1alectinib 1Tretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Digestive System Neoplasms × donafenib × Clear all
NCT04962958 2023-06-22

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Carcinoma, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡